Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.19 USD | +2.57% | -2.45% | +57.92% |
May. 10 | Leerink Partners Starts Aquestive Therapeutics With Outperform Rating, $8 Price Target | MT |
May. 08 | Transcript : Aquestive Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024 |
Financials (USD)
Sales 2024 * | 50.02M | Sales 2025 * | 58.76M | Capitalization | 283M |
---|---|---|---|---|---|
Net income 2024 * | -45M | Net income 2025 * | -37M | EV / Sales 2024 * | 5.61 x |
Net cash position 2024 * | 2.63M | Net Debt 2025 * | 15.47M | EV / Sales 2025 * | 5.08 x |
P/E ratio 2024 * |
-5.74
x | P/E ratio 2025 * |
-7.49
x | Employees | 135 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.06% |
Latest transcript on Aquestive Therapeutics, Inc.
1 day | +2.57% | ||
1 week | -2.45% | ||
Current month | -5.06% | ||
1 month | -22.29% | ||
3 months | +20.38% | ||
6 months | +78.21% | ||
Current year | +57.92% |
Managers | Title | Age | Since |
---|---|---|---|
Daniel Barber
CEO | Chief Executive Officer | 48 | 07-06-30 |
A. Toth
DFI | Director of Finance/CFO | 65 | 20-12-30 |
Stephen Wargacki
CTO | Chief Tech/Sci/R&D Officer | 46 | 14-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Timothy Morris
BRD | Director/Board Member | 61 | 22-08-09 |
Santo Costa
BRD | Director/Board Member | 78 | 15-11-30 |
Gregory Brown
CHM | Chairman | 70 | 07-02-28 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-20 | 3.19 | +2.57% | 653,601 |
24-05-17 | 3.11 | -5.18% | 837,219 |
24-05-16 | 3.28 | +1.86% | 629,299 |
24-05-15 | 3.22 | +0.63% | 941,661 |
24-05-14 | 3.2 | -2.14% | 1,125,453 |
Delayed Quote Nasdaq, May 20, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+57.92% | 283M | |
+34.35% | 693B | |
+29.39% | 584B | |
-3.49% | 372B | |
+20.15% | 332B | |
+6.19% | 294B | |
+14.11% | 239B | |
-3.03% | 211B | |
+10.02% | 210B | |
+9.21% | 168B |
- Stock Market
- Equities
- AQST Stock